Skip to main content
Erschienen in: Clinical Rheumatology 1/2016

01.01.2016 | Brief Report

Development of de novo major involvement during follow-up in Behçet’s syndrome

verfasst von: Rosaria Talarico, Luca Cantarini, Anna d’Ascanio, Michele Figus, Benedetta Favati, Chiara Baldini, Chiara Tani, R. Neri, Stefano Bombardieri, Marta Mosca

Erschienen in: Clinical Rheumatology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The primary aim of the study was to evaluate the incidence of de novo major involvement during follow-up in a cohort of patients with Behçet’s syndrome (BS); the secondary aim was to analyse the epidemiological profile and the long-term outcome of those patients who developed new major involvement. Among our cohort of 120 BS patients, we evaluated all subjects who had no major organ involvement during the early years of their disease; specifically, at disease onset, the 52 % of the cohort presented a prevalent mucocutaneous involvement. The primary outcomes were represented by the following: Hatemi et al. (Rheum Dis Clin North Am 39(2):245–61, 2013) the incidence of de novo major involvement during the follow-up and Hatemi et al. (Clin Exp Rheumatol 32(4 Suppl 84):S112–22, 2014) the use of immunosuppressive drugs during the follow-up. We have defined the development of de novo major involvement during the follow-up as the occurrence of severe ocular, vascular or CNS involvement after a latency period from the diagnosis of at least 3 years. Among 62 patients characterized by a mild onset of disease, we observed that after at least 3 years from the diagnosis, 21 BS patients (34 %) still developed serious morbidities. Specifically, three patients developed ocular involvement, nine patients developed neurological involvement and nine patients presented vascular involvement. Comparing main epidemiological and clinical findings of the two groups, we observed that patients who developed de novo major involvement were more frequently males and younger; furthermore, 95 % of these patients were characterized by a young onset of disease (p < 0.001). Being free of major organ complication in the first years of BS is not necessary a sign of a favourable outcome. Globally, the development of de novo major involvement during the coursfce of BS suggests that a tight control is strongly recommended during the course of the disease.
Literatur
1.
Zurück zum Zitat Hatemi G, Yazici Y, Yazici H (2013) Behçet's syndrome. Rheum Dis Clin North Am 39(2):245–261PubMedCrossRef Hatemi G, Yazici Y, Yazici H (2013) Behçet's syndrome. Rheum Dis Clin North Am 39(2):245–261PubMedCrossRef
2.
Zurück zum Zitat Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2014) Behçet’s syndrome: a critical digest of the 2013–2014 literature. Clin Exp Rheumatol 32(4 Suppl 84):S112–S122PubMed Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2014) Behçet’s syndrome: a critical digest of the 2013–2014 literature. Clin Exp Rheumatol 32(4 Suppl 84):S112–S122PubMed
3.
Zurück zum Zitat Koné-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, Kuemmerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, Letierce A, Tran TA, PED-BD International Expert Committee (2011) Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 50:184–188. doi:10.1093/rheumatology/keq324 CrossRef Koné-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, Kuemmerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, Letierce A, Tran TA, PED-BD International Expert Committee (2011) Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford) 50:184–188. doi:10.​1093/​rheumatology/​keq324 CrossRef
4.
Zurück zum Zitat Vitale A, Rigante D, Lopalco G, Brizi MG, Caso F, Franceschini R, Denaro R, Galeazzi M, Punzi L, Iannone F, Lapadula G, Simpatico A, Marrani E, Costa L, Cimaz R, Cantarini L (2014) Serum amyloid-A in Behçet’s disease. Clin Rheumatol 33(8):1165–1167PubMedCrossRef Vitale A, Rigante D, Lopalco G, Brizi MG, Caso F, Franceschini R, Denaro R, Galeazzi M, Punzi L, Iannone F, Lapadula G, Simpatico A, Marrani E, Costa L, Cimaz R, Cantarini L (2014) Serum amyloid-A in Behçet’s disease. Clin Rheumatol 33(8):1165–1167PubMedCrossRef
5.
Zurück zum Zitat Hatemi G, Yazici H (2011) Behçet’s syndrome and micro-organisms. Best Pract Res Clin Rheumatol 25(3):389–406PubMedCrossRef Hatemi G, Yazici H (2011) Behçet’s syndrome and micro-organisms. Best Pract Res Clin Rheumatol 25(3):389–406PubMedCrossRef
6.
Zurück zum Zitat Yazici H, Ugurlu S, Seyahi E (2012) Behçet syndrome: is it one condition? Clin Rev Allergy Immunol 43(3):275–280PubMedCrossRef Yazici H, Ugurlu S, Seyahi E (2012) Behçet syndrome: is it one condition? Clin Rev Allergy Immunol 43(3):275–280PubMedCrossRef
7.
Zurück zum Zitat Cantarini L, Vitale A, Lucherini OM, De Clemente C, Caso F, Costa L, Emmi G, Silvestri E, Magnotti F, Maggio MC, Prinzi E, Lopalco G, Frediani B, Cimaz R, Galeazzi M, Rigante D (2014) The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clin Rheumatol Cantarini L, Vitale A, Lucherini OM, De Clemente C, Caso F, Costa L, Emmi G, Silvestri E, Magnotti F, Maggio MC, Prinzi E, Lopalco G, Frediani B, Cimaz R, Galeazzi M, Rigante D (2014) The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clin Rheumatol
8.
Zurück zum Zitat Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol 30(3 Suppl 72):S115PubMed Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol 30(3 Suppl 72):S115PubMed
9.
Zurück zum Zitat Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B, Bertoldi I, Punzi L, Galeazzi M, Cimaz R (2013) Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. doi:10.1007/s10067-013-2443-8 Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B, Bertoldi I, Punzi L, Galeazzi M, Cimaz R (2013) Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. doi:10.​1007/​s10067-013-2443-8
10.
Zurück zum Zitat Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmun Rev 14:1–9PubMedCrossRef Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmun Rev 14:1–9PubMedCrossRef
11.
Zurück zum Zitat International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–80 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–80
12.
Zurück zum Zitat Yazici H, Esen F (2008) Mortality in Behçet’s syndrome. Clin Exp Rheumatol 26(Suppl 51):S138–S140PubMed Yazici H, Esen F (2008) Mortality in Behçet’s syndrome. Clin Exp Rheumatol 26(Suppl 51):S138–S140PubMed
13.
Zurück zum Zitat Talarico R, d'Ascanio A, Figus M, Stagnaro C, Ferrari C, Elefante E et al (2012) Behçet’s disease: features of neurological involvement in a dedicated centre in Italy. Clin Exp Rheumatol 30(3 Suppl 72):S69–S72PubMed Talarico R, d'Ascanio A, Figus M, Stagnaro C, Ferrari C, Elefante E et al (2012) Behçet’s disease: features of neurological involvement in a dedicated centre in Italy. Clin Exp Rheumatol 30(3 Suppl 72):S69–S72PubMed
14.
Zurück zum Zitat Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122(Pt 11):2171–2182PubMedCrossRef Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122(Pt 11):2171–2182PubMedCrossRef
15.
Zurück zum Zitat Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42:346–351PubMedCrossRef Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42:346–351PubMedCrossRef
16.
Zurück zum Zitat Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, Mat C, Yurdakul S, Yazici H (2010) Prognosis of Behcet’s syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 4(1):173–177CrossRef Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, Mat C, Yurdakul S, Yazici H (2010) Prognosis of Behcet’s syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 4(1):173–177CrossRef
17.
Zurück zum Zitat Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, Kandi B, Buyukkara S, Keseroglu O, Uzun S, Tursen U, Seyhan M, Akman A (2007) Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol 157(5):901–906PubMedCrossRef Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, Kandi B, Buyukkara S, Keseroglu O, Uzun S, Tursen U, Seyhan M, Akman A (2007) Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol 157(5):901–906PubMedCrossRef
18.
Zurück zum Zitat Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60–76PubMedCrossRef Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60–76PubMedCrossRef
19.
Zurück zum Zitat Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380PubMedCrossRef Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380PubMedCrossRef
20.
Zurück zum Zitat Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, Can M, Oner SY, Inanc N, Atagunduz P, Ergun T, Direskeneli H (2014) Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol 33(12):1773–1776PubMedCrossRef Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, Can M, Oner SY, Inanc N, Atagunduz P, Ergun T, Direskeneli H (2014) Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol 33(12):1773–1776PubMedCrossRef
21.
Zurück zum Zitat Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martín L, Atteno M, Raffaele CG, Tarantino G, Galeazzi M, Punzi L, Cantarini L (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediat Inflamm. doi:10.1155/2014/107421 Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martín L, Atteno M, Raffaele CG, Tarantino G, Galeazzi M, Punzi L, Cantarini L (2014) Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediat Inflamm. doi:10.​1155/​2014/​107421
22.
Zurück zum Zitat Ozguler Y, Hatemi G, Yazici H (2014) Management of Behçet’s syndrome. Curr Opin Rheumatol 26(3):285–291PubMedCrossRef Ozguler Y, Hatemi G, Yazici H (2014) Management of Behçet’s syndrome. Curr Opin Rheumatol 26(3):285–291PubMedCrossRef
Metadaten
Titel
Development of de novo major involvement during follow-up in Behçet’s syndrome
verfasst von
Rosaria Talarico
Luca Cantarini
Anna d’Ascanio
Michele Figus
Benedetta Favati
Chiara Baldini
Chiara Tani
R. Neri
Stefano Bombardieri
Marta Mosca
Publikationsdatum
01.01.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 1/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2906-1

Weitere Artikel der Ausgabe 1/2016

Clinical Rheumatology 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.